

SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report.

SynAct Pharma AB (publ) ("SynAct") has decided to bring forward the publication of the annual report for the financial year 2023 to March 26, 2024.

The previous date for publication of the Annual Report for the financial year 2023 was April 10, 2024, but is now brought forward to March 26, 2024.

For further information, please contact:

CFO, Björn Westberg

Telefon: +46 703 33 91 23

E-post: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolving activity to help patients achieve immune balance and overcome their inflammation. For more information, please contact: www.synactpharma.com.

Attachments

[SynAct Pharma AB \(publ\) \("SynAct"\) brings forward the publication of the annual report.](#)